We are a biotech startup in the San Francisco Bay Area founded in February 2017. We focus on developing complex antibodies with enhanced efficacy, safety, and manufacturability features against difficult-to-treat diseases including cancer, infectious diseases, and CNS diseases, by combining conventional approaches with computer-aided antibody design (CAAD). Our founder and lead scientists have extensive expertise in the fields of therapeutic antibody discovery, lead selection, engineering, humanization, and optimization.

Our goal is to close the gap between antibody discovery and therapeutic antibody development by developing the next generation of therapeutic antibodies. We believe in quality-by-design and have established several CAAD-based unique technology platforms for antibody development and are in the process of developing more platforms and therapeutics.

3541 Investment Blvd. Suite 3,
Hayward, CA 94545 USA